Clinical Trials
33 trialsCUPem
Imperial College London
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
CUPISCO
Hoffmann-La Roche
CAPTIV-8
British Columbia Cancer Agency
CUP
AHS Cancer Control Alberta
ACROPOLI
SOLTI Breast Cancer Research Group
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
TOFFEE
University of Edinburgh
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Burzynski Research Institute
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
Eastern Cooperative Oncology Group
CheCUP
University Hospital Heidelberg
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
St. Jude Children's Research Hospital
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Samsung Medical Center
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Rutgers, The State University of New Jersey
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
Fox Chase Cancer Center
Gemox as First and Second Line Therapy in Unknown Primary Cancer
M.D. Anderson Cancer Center
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
National Cancer Institute (NCI)
PACET-CUP
Heidelberg University
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
University of Michigan Rogel Cancer Center